Pmv Pharmaceuticals Inc (PMVP) Stock Price, Quote & News

Latest News on PMVP

Mar 3, 2025, 8:00 AM EST - 6 weeks ago

PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights

Feb 11, 2025, 8:00 AM EST - 2 months ago

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences

May 29, 2024, 7:00 AM EDT - 11 months ago

Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator

May 9, 2024, 8:00 AM EDT - 1 year ago

PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights

Mar 27, 2024, 8:00 AM EDT - 1 year ago

PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors

Mar 18, 2024, 4:01 PM EDT - 1 year ago

PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's Cancer

Feb 29, 2024, 4:01 PM EST - 1 year ago

PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights

Jan 18, 2024, 4:01 PM EST - 1 year ago

PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway

Jan 5, 2024, 4:01 PM EST - 1 year ago

PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development

Nov 14, 2023, 6:50 PM EST - 1 year ago

PMV Pharmaceuticals: In A Stronger Position Now Than Before, At A Lower Price

Nov 9, 2023, 8:00 AM EST - 1 year ago

PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights

Oct 12, 2023, 12:30 PM EDT - 1 year ago

PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation

Oct 11, 2023, 12:00 PM EDT - 1 year ago

PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL Webinar

Sep 20, 2023, 4:05 PM EDT - 1 year ago

PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Aug 30, 2023, 9:20 AM EDT - 1 year ago

PMV Pharmaceuticals: A 5-Month Run-Up Is Justified

Aug 9, 2023, 8:00 AM EDT - 1 year ago

PMV Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Highlights

Jun 6, 2023, 4:01 PM EDT - 2 years ago

PMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare Conference

May 10, 2023, 8:00 AM EDT - 2 years ago

PMV Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Highlights

Mar 1, 2023, 8:00 AM EST - 2 years ago

PMV Pharmaceuticals Reports Full Year 2022 Financial Results and Corporate Highlights

Feb 28, 2023, 4:05 PM EST - 2 years ago

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in March

Nov 22, 2022, 8:00 AM EST - 2 years ago

PMV Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference

Nov 8, 2022, 8:00 AM EST - 2 years ago

PMV Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights

Nov 4, 2022, 8:00 AM EDT - 2 years ago

PMV Pharmaceuticals Appoints Industry Veteran Dr. Carol Gallagher to Board of Directors

Aug 9, 2022, 8:00 AM EDT - 2 years ago

PMV Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights

Jul 18, 2022, 8:00 AM EDT - 2 years ago

PMV Pharmaceuticals Announces a Clinical Trial Collaboration with Merck to Evaluate PC14586 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors

Jun 7, 2022, 12:00 PM EDT - 3 years ago

PMV Pharmaceuticals Initial PC14586 Phase 1 Data Presented at ASCO Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a p53 Y220C Mutation

May 26, 2022, 5:05 PM EDT - 3 years ago

PMV Pharmaceuticals Announces Initial PC14586 Phase 1 Clinical Data to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

May 10, 2022, 7:30 AM EDT - 3 years ago

PMV Pharmaceuticals Reports First Quarter 2022 Financial Results and Corporate Highlights

Apr 27, 2022, 10:30 AM EDT - 3 years ago

PMV Pharmaceuticals to Present PC14586 Phase 1 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Mar 1, 2022, 7:15 AM EST - 3 years ago

PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights

Feb 28, 2022, 8:00 AM EST - 3 years ago

PMV Pharmaceuticals to Participate in the 42nd Annual Cowen Health Care Conference

Feb 3, 2022, 8:00 AM EST - 3 years ago

PMV Pharmaceuticals to Participate in the Guggenheim Healthcare Talks 2022 Oncology Day

Jan 6, 2022, 8:00 AM EST - 3 years ago

PMV Pharma Announces Changes to its Board of Directors

Nov 22, 2021, 8:00 AM EST - 3 years ago

PMV Pharma to Present at the Evercore ISI 4th Annual HealthCONx Conference

Nov 12, 2021, 7:15 AM EST - 3 years ago

PMV Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Highlights

Sep 2, 2021, 8:00 AM EDT - 3 years ago

PMV Pharmaceuticals to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

Aug 13, 2021, 8:00 AM EDT - 4 years ago

PMV Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Highlights

Jun 9, 2021, 8:00 AM EDT - 4 years ago

PMV Pharmaceuticals Announces Participation at the Bank of America Securities 2021 Napa Biopharma Virtual Conference

May 14, 2021, 8:00 AM EDT - 4 years ago

PMV Pharmaceuticals Reports First Quarter 2021 Financial Results and Corporate Highlights

May 5, 2021, 8:00 AM EDT - 4 years ago

PMV Pharmaceuticals Announces Participation at the Bank of America Healthcare Conference

Apr 10, 2021, 1:31 PM EDT - 4 years ago

PMV Pharma Presents Late-Breaking Preclinical Data on Lead Product Candidate PC14586 at the American Association for Cancer Research Annual Meeting 2021

Apr 6, 2021, 8:00 AM EDT - 4 years ago

PMV Pharma Strengthens Board of Directors with Appointment of Dr. Charles Baum

Mar 10, 2021, 4:31 PM EST - 4 years ago

PMV Pharmaceuticals Announces Presentation of PC14586 Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2021

Mar 3, 2021, 4:01 PM EST - 4 years ago

PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights

Feb 16, 2021, 8:00 AM EST - 4 years ago

PMV Pharma Appoints p53 Pioneer Dr. Guillermina Lozano to Scientific Advisory Board

Nov 24, 2020, 5:00 PM EST - 4 years ago

PMV Pharmaceuticals to Present at Evercore ISI 3rd Annual HealthCONx Conference

Nov 23, 2020, 8:00 AM EST - 4 years ago

PMV Pharma Doses First Patient in Phase 1/2 Study of PC14586, a First-in-Class Precision Oncology Therapy That Targets Mutant p53

Nov 13, 2020, 8:00 AM EST - 4 years ago

PMV Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Highlights

Oct 6, 2020, 4:16 PM EDT - 4 years ago

Andreas Halvorsen Jumps on PMV Pharmaceuticals

Sep 29, 2020, 4:05 PM EDT - 4 years ago

Market Cap	52.97M
Revenue (ttm)	0.00
Net Income (ttm)	-58.71M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	89,400
Avg Vol	123,496
Day's Range	N/A - N/A
Shares Out	51.93M
Stochastic %K	87%
Beta	1.49
Analysts	Strong Sell
Price Target	$5.80